New Publication Highlights Basic Science Supporting Simufilam
- Publication Reviews Certain Receptor-Protein Interactions.
- Provides Overview of Basic Science Supporting Simufilam.
- Published in
Drug Development Research , aPeer-Reviewed Journal .
“This paper highlights the role of altered filamin A and its receptor interactions in Alzheimer's disease,” said
The review article was published on-line
Access to the full text is subject to the publisher’s copyright and fee policies. The citation is: “Burns LH, Pei Z, Wang HY. Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development. Drug
About Simufilam
Simufilam is a novel drug candidate designed to treat and slow the progression of Alzheimer’s disease. Simufilam binds tightly to an altered conformation of the filamin A protein (FLNA) that is present in the brain of the Alzheimer’s patient and is critical to the toxicity of Aβ42. Simufilam is wholly owned by
About
For More Information Contact:
(512) 501-2450, or ESchoen@CassavaSciences.com
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to: our basic research in support of simufilam; the design, scope, conduct or intended purpose of our Phase 3 program of simufilam in patients with Alzheimer's disease; the safety or expected effects of simufilam in Alzheimer’s disease, if any; any expected clinical results of Phase 3 studies; the treatment of people with Alzheimer’s disease dementia; the safety or efficacy of simufilam in people with Alzheimer’s disease dementia; verbal commentaries made by our employees; and potential benefits, if any, of the our product candidates. These statements may be identified by words such as “may,” “anticipate,” “believe,” “could,” “expect,” “forecast,” “intend,” “plan,” “possible,” “potential,” and other words and terms of similar meaning.
Simufilam is our investigational product candidates. It is not approved by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes have not been established in patients. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Clinical results from our prior studies may not be indicative of results of future or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of inflation on our business operations, and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended
Source: Cassava Sciences, Inc.